Previous studies have indicated that the sensitivity of
breast cancer cells to
tumor necrosis factor‑related apoptosis‑inducing
ligand (TRAIL)‑induced apoptosis is associated with the expression of
death receptors on the cell membrane. However, drug resistance limits the use of TRAIL in
cancer therapy. Numerous studies have indicated that
death receptors, which induce apoptosis, are upregulated by the endoplasmic reticulum (ER) stress response. 3‑Bromopyruvate (3‑BP), an
anticancer agent, inhibits cell growth and induces apoptosis through interfering with glycolysis. In the present study, it was demonstrated that 3‑BP synergistically sensitized
breast cancer cells to TRAIL‑induced apoptosis via the upregulation of death receptor 5 (DR5). Furthermore, we found that the
protein levels of glucose‑related protein 78 (
GRP78) and CCAAT‑enhancer‑binding
protein homologous
protein (CHOP) increased following treatment with 3‑BP. The expression of Bax (in MCF‑7 cells) and caspase‑3 (in MDA‑MB‑231 cells) increased following co‑treatment with 3‑BP and TRAIL, whereas the expression of the anti‑apoptotic
protein Bcl‑2 decreased. In order to investigate the molecular mechanism regulating this effect, the expression of
adenosine monophosphate‑activated
protein kinase (AMPK), activated by 3‑BP, was determined. It was demonstrated that phosphorylated‑AMPK was upregulated following treatment with 3‑BP. Notably, Compound C, an AMPK inhibitor, reversed the effects of 3‑BP. Finally, a synergistic antitumor effect of 3‑BP and TRAIL was observed in MCF‑7 cell xenografts in nude mice. In conclusion, these results indicated that 3‑BP sensitized
breast cancer cells to TRAIL via the AMPK‑mediated upregulation of DR5.